In this study, progression was assessed using PSA criteria only; however, in mCRPC, progression may also be defined by PSA, radiographic, or clinical measures per Prostate Cancer Working Group 3 criteria, which were not incorporated here. The gene discussed is KLK3; the disease is prostate cancer.